title: Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazine.
abstract: The relationship between the cytochrome P450 (CYP) 2D6 genotype and the steady-state plasma concentrations (Css) of trazodone and its active metabolite m-chlorophenylpiperazine (mCPP) was studied in 54 depressed Japanese patients receiving trazodone 150 mg at bedtime. By use of allele-specific PCR analysis, the wild type allele, three mutated alleles causing absent enzyme activity (CYP2D6A, CYP2D6B and CYP2D6D) and one mutated allele causing decreased enzyme activity (CYPZD6 Ch) were identified. The means (ranges) of the Css of trazodone, corrected to the median body weight in 17 cases with no mutated allele, 27 cases with one mutated allele and 10 cases with two mutated alleles, were 556 (281-1115), 643 (302-1362) and 671 (234-1418) ng/ml, respectively, while the values of mCPP were 60 (35-121), 65 (33-99) and 58 (38-112) ng/ml, respectively. Neither the Css of trazodone (F = 0.80, P = 0.45) nor that of mCPP (F = 0.49, P = 0.61) significantly differed among the three groups. The present study thus suggests that the CYP2D6 genotype cannot predict the Css of these compounds.
authors.affiliation: Department of Neuropsychiatry, Hirosaki University Hospital, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Mihara
authors.forename: K
authors.initials: K
authors.lastname: Otani
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: N
authors.initials: N
authors.lastname: Yasui
authors.forename: H
authors.initials: H
authors.lastname: Nakano
authors.forename: X
authors.initials: X
authors.lastname: Meng
authors.forename: T
authors.initials: T
authors.lastname: Ohkubo
authors.forename: T
authors.initials: T
authors.lastname: Nagasaki
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
authors.forename: S
authors.initials: S
authors.lastname: Tsuchida
authors.forename: K
authors.initials: K
authors.lastname: Sugawara
authors.forename: F J
authors.initials: FJ
authors.lastname: Gonzalez
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000097:blood* / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics* / Q000378:metabolism; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010597:Pharmacogenetics; D010879:Piperazines / Q000097:blood*; D017367:Selective Serotonin Reuptake Inhibitors / Q000097:blood* / Q000627:therapeutic use; D014196:Trazodone / Q000097:blood* / Q000627:therapeutic use
chemical_list: D018687:Antidepressive Agents, Second-Generation; D019389:Cytochrome P-450 CYP2D6; D010879:Piperazines; D017367:Selective Serotonin Reuptake Inhibitors; D014196:Trazodone; C015068:1-(3-chlorophenyl)piperazine